AmacaThera
AmacaThera is a clinical-stage biotechnology company dedicated to transforming therapeutics through innovative drug delivery platforms. Their unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas, including post-surgical pain management, cancer, and hard-to-reach targets. The company aims to revolutionize treatment options using advanced hydrogel formulations, with a focus on reducing opioid dependency and addressing unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Products
AMT‑143 (lead sustained‑release local anesthetic)
A slow‑release, non‑opioid local anesthetic formulation designed for single‑administration, localized post‑operative pain control delivered via an injectable hydrogel depot.
Injectable thermoresponsive hydrogel platform
A fast‑gelling thermoresponsive hydrogel platform designed to liquefy under shear for syringe delivery and gel at body temperature to form a local depot compatible with small molecules, biologics, lipid nanoparticles and cells.
AMT‑143 (lead sustained‑release local anesthetic)
A slow‑release, non‑opioid local anesthetic formulation designed for single‑administration, localized post‑operative pain control delivered via an injectable hydrogel depot.
Injectable thermoresponsive hydrogel platform
A fast‑gelling thermoresponsive hydrogel platform designed to liquefy under shear for syringe delivery and gel at body temperature to form a local depot compatible with small molecules, biologics, lipid nanoparticles and cells.
Services
Collaborative development and evaluation agreements
Partnered evaluation and option agreements to co‑develop long‑acting injectable formulations for new markets, including veterinary and human health applications.
Preclinical formulation and PK evaluation
Formulation development and preclinical testing services focusing on sustained‑release local delivery, release kinetics, and payload compatibility.
Clinical development and early‑phase trial execution
Clinical program management for first‑in‑human and early efficacy studies including safety, tolerability, pharmacokinetics and clinical activity endpoints for local depot formulations.
Collaborative development and evaluation agreements
Partnered evaluation and option agreements to co‑develop long‑acting injectable formulations for new markets, including veterinary and human health applications.
Preclinical formulation and PK evaluation
Formulation development and preclinical testing services focusing on sustained‑release local delivery, release kinetics, and payload compatibility.
Clinical development and early‑phase trial execution
Clinical program management for first‑in‑human and early efficacy studies including safety, tolerability, pharmacokinetics and clinical activity endpoints for local depot formulations.
Expertise Areas
- Localized sustained‑release drug delivery
- Hydrogel biomaterials for therapeutic delivery
- Clinical trial management (Phase I and early Phase II)
- Sterile injectable manufacturing and scale‑up
Key Technologies
- Thermoresponsive, shear‑thinning hydrogel materials
- Injectable depot formation at body temperature
- Controlled‑release formulation technologies
- Pharmacokinetic and release‑kinetics assays